What is the difference between immediate-release and prolonged-release melatonin?

Immediate-release (IR) melatonin dissolves quickly and produces a rapid spike in serum melatonin, typically within 1 hour, then clears within a few hours. Prolonged-release (PR) formulations use a matrix to slow dissolution, producing a more gradual curve that studies suggest may better mimic the body's natural overnight secretion profile. A randomized crossover pharmacokinetic trial in 14 volunteers found PR maintained serum levels approximately 3× higher than IR at 4–6 hours post-dose (PMID 35918587).

What dose of melatonin do studies typically use?

Published randomized trials have used a wide range. A double-blind trial in 116 participants used 0.5 mg fast-release melatonin (PMID 29912983). A sleep-medicine consensus review recommends 2 mg slow-release melatonin taken 1–2 h before bed for 3–12 weeks (PMID 32921425). Higher doses (3–6 mg) appear in other protocols. Lower doses are generally preferred as starting points given melatonin's hormonal nature.

Is melatonin a supplement or a drug?

In the United States, melatonin is sold as a dietary supplement for structure/function purposes such as supporting healthy sleep. In some European countries, prolonged-release melatonin formulations at prescription doses are registered as medications for specific sleep disorders. This page covers the supplement context only; if you have a diagnosed sleep condition, please consult a healthcare provider.

Can I take melatonin every night?

Short-term use (3–12 weeks) at low doses has been studied without significant adverse effects reported in published trials. A consensus review noted slow-release melatonin at 2 mg showed no serious side effects and no withdrawal symptoms across studies (PMID 32921425). Long-term supplementation has not been as well characterized; consult a healthcare provider for guidance on ongoing use.

Moderate Evidence

Best Form of Melatonin

The form of melatonin you take may affect how quickly you fall asleep vs how well you stay asleep — studies suggest immediate-release acts faster while prolonged-release may extend the release curve to more closely mimic the body's natural overnight melatonin profile.

Updated 2026 · Reviewed by Dr. Brennan Commerford, D.C.

All Forms Ranked by Evidence

1
100/ 100· Top TierBest by EvidenceFF Preferred
Melatonin
Form: Immediate Release
—
Verification pending
Melatonin (Standard Powder)
Form: Standard Powder
Evidence for this form is under review — no score is shown until it is verified.

Editorial note

A randomized crossover pharmacokinetic trial in 14 healthy volunteers found that a prolonged-release (PR) melatonin formulation maintained serum concentrations approximately 3× higher than immediate-release at 4–6 h post-administration, with detectable levels above the endogenous melatonin peak for ~2.5 h longer — consistent with potential support for sleep maintenance as well as onset (PMID 35918587). For sleep-onset latency specifically, a double-blind randomized trial in 116 participants found fast-release 0.5 mg melatonin taken 1 h before bedtime was associated with sleep onset occurring ~34 min earlier vs placebo (PMID 29912983).

All Forms Compared

Prolonged-Release (PR/ER)

Best For

Sleep maintenance, mimicking the endogenous overnight melatonin curve

A randomized crossover PK trial in 14 volunteers found PR maintained serum levels ~3× higher than IR at 4–6 h (PMID 35918587). A consensus review of Level-A studies found 2 mg slow-release melatonin 1–2 h before bed may decrease sleep latency and improve sleep quality without next-day withdrawal effects (PMID 32921425).

Immediate-Release (IR)

Best For

Sleep-onset latency, circadian phase-shifting, jet lag

A double-blind randomized trial in 116 participants found 0.5 mg fast-release melatonin 1 h pre-bed associated with sleep onset ~34 min earlier vs placebo (PMID 29912983). Doses used in studies range widely from 0.5 mg to 6 mg.

Sublingual / Liquid

Best For

Fastest possible sleep-onset support; acute use

Direct human PK head-to-head comparisons vs IR tablets are limited in the published literature. Theoretical rationale is sublingual absorption bypassing hepatic first-pass; use the lowest effective dose.

Standard Tablet (unspecified release)

Best For

Not recommended when release profile is unstated

Without a declared release profile, the pharmacokinetic behavior is unclear. Studies consistently test a defined IR or PR formulation — unspecified products provide no guarantee of which effect you are targeting.

Frequently Asked Questions

What is the difference between immediate-release and prolonged-release melatonin?: Immediate-release (IR) melatonin dissolves quickly and produces a rapid spike in serum melatonin, typically within 1 hour, then clears within a few hours. Prolonged-release (PR) formulations use a matrix to slow dissolution, producing a more gradual curve that studies suggest may better mimic the body's natural overnight secretion profile. A randomized crossover pharmacokinetic trial in 14 volunteers found PR maintained serum levels approximately 3× higher than IR at 4–6 hours post-dose (PMID 35918587).
What dose of melatonin do studies typically use?: Published randomized trials have used a wide range. A double-blind trial in 116 participants used 0.5 mg fast-release melatonin (PMID 29912983). A sleep-medicine consensus review recommends 2 mg slow-release melatonin taken 1–2 h before bed for 3–12 weeks (PMID 32921425). Higher doses (3–6 mg) appear in other protocols. Lower doses are generally preferred as starting points given melatonin's hormonal nature.
Is melatonin a supplement or a drug?: In the United States, melatonin is sold as a dietary supplement for structure/function purposes such as supporting healthy sleep. In some European countries, prolonged-release melatonin formulations at prescription doses are registered as medications for specific sleep disorders. This page covers the supplement context only; if you have a diagnosed sleep condition, please consult a healthcare provider.
Can I take melatonin every night?: Short-term use (3–12 weeks) at low doses has been studied without significant adverse effects reported in published trials. A consensus review noted slow-release melatonin at 2 mg showed no serious side effects and no withdrawal symptoms across studies (PMID 32921425). Long-term supplementation has not been as well characterized; consult a healthcare provider for guidance on ongoing use.

See how Prolonged-Release (PR/ER) fits your formula

Preview a personalized formula using research-backed dosing.

Preview your formula →

Deep dive: Prolonged-Release (for sleep maintenance) research

Full ingredient spotlight with citations

View spotlight

FormulaForge formulates and sells supplements containing the ingredients discussed on this page. Our formulary recommendations are based on peer-reviewed bioavailability research. All cited studies are independently verifiable.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.